about the author

Endpoints Contributor

help@endpts.com

author articles

Reg­u­la­to­ry in­tel­li­gence: Up­date on re­gen­er­a­tive med­i­cine ad­vanced ther­a­pies des­ig­na­tions

7 years ago
Cell/Gene Tx

Boost­ing check­point in­hibitor ef­fi­ca­cy via the mi­cro­bio­me

7 years ago

Whale watch­ing: What a decade of change at Big Phar­ma taught us about cor­po­rate phe­no­types

7 years ago
Deals
Biotech Voices

Phar­ma’s sum­mer of punk: Who's play­ing the hits — or tak­ing a hit — on the world in­no­va­tion tour

7 years ago
R&D
Biotech Voices

How the sur­gi­cal set­ting con­tributes to the opi­oid cri­sis

7 years ago

Fol­licum, a Swedish biotech com­pa­ny born to find a treat­ment for hair loss, now has di­a­betes in its crosshairs

7 years ago

Phar­ma, we have a prob­lem: New drugs can't cov­er the cost of Big Phar­ma's fail­ures

7 years ago
R&D
Biotech Voices

Cel­gene's top 20 up­front hits: Just how gen­er­ous was Cel­gene in deal­mak­ing? Let's re­view the records

7 years ago
Pharma

May the can­dle burn for­ev­er: Po­lite re­minders about the JP­Mor­gan con­fab

7 years ago
Biotech Voices

Ap­ta­hem – a Swedish biotech aim­ing to win the race against sep­sis

7 years ago

Fo­cus on tar­get­ed val­ue cre­ation and in­creased strate­gic man­age­ment is key to ad­dress chal­lenges with R&D ...

7 years ago

Io­n­is is fo­cused on treat­ing the un­treat­able with med­ical break­throughs for pa­tients

7 years ago

Cereno Sci­en­tif­ic is dri­ving a new par­a­digm of throm­bo­sis pre­ven­tion with­out as­so­ci­at­ed bleed­ing-risks

7 years ago

Nov­el he­pati­tis B virus nu­cle­o­cap­sid for­ma­tion in­hibitor CB-HBV-001 demon­strates ex­cel­lent an­ti-HBV ac­tiv­i­ty

7 years ago

How tri­al in­no­va­tion in Aus­tralia is get­ting ther­a­pies to pa­tients soon­er

7 years ago

With ac­cess to 1.4 bil­lion po­ten­tial Asia-Pa­cif­ic tri­al par­tic­i­pants, Novotech CRO can help get your drug to mar­ket ...

7 years ago

Guest col­umn: The re­al cost of drug de­vel­op­ment

7 years ago
R&D
Biotech Voices

A Swedish biotech is tar­get­ing throm­bo­sis us­ing the body's own de­fense sys­tem to pre­vent blood clots with low­er risk ...

7 years ago

The first FDA-ap­proved dig­i­tal pill — what it means for phar­ma

7 years ago

Guest col­umn: The 3 big waves re­shap­ing in­vest­ment strate­gies in ear­ly-stage biotech

7 years ago
Financing
Startups

Is the phar­ma busi­ness mod­el ready for pre­ci­sion med­i­cine?

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Sup­ply and De­mand Ex­pec­ta­tions and Im­bal­ances

7 years ago

Swedish Biotech Dex­Tech Med­ical shoots for bil­lion dol­lar prostate can­cer mar­ket — con­cludes phI­Ib study ear­ly

7 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Bull­ish Run to Con­tin­ue Amidst Signs of Greater Risk Aver­sion

7 years ago
First page Previous page 89101112 Next page Last page
A service from the Financial Times